Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02254317 · ClinicalTrials.gov registry record · NA
Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance
A NA study, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
NCT02254317: Completed NA study, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
NCT02254317 is a NA study that has completed, run by Clinical Nutrition Research Center, Illinois Institute of Technology. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02254317, a NA study, has completed, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
Study Summary
The objective is to identify the lowest effective dose of Grape Seed Extract (GSE) on glucose control in people with impaired glucose tolerance (IGT).
Primary Outcome
plasma metabolic markers over 4 hour Oral Glucose Tolerance Test (OGTT)
Interventions
- DIETARY_SUPPLEMENT 0 mg placebo
- DIETARY_SUPPLEMENT 300 mg GSE
- DIETARY_SUPPLEMENT 600 mg GSE
- DIETARY_SUPPLEMENT 900 mg GSE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-09-15 |
| Est. Completion | 2015-07-01 |
| Phase | NA |
What the finished NCT02254317 record still lists
NCT02254317 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 4 interventions - of which 0 mg placebo is the first listed.
NCT02254317 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02254317 about?
NCT02254317 is a clinical study titled "Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance". The objective is to identify the lowest effective dose of Grape Seed Extract (GSE) on glucose control in people with impaired glucose tolerance (IGT).
What is the current status of trial NCT02254317?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2014-09-15. Estimated completion is 2015-07-01.
What interventions are being tested in trial NCT02254317?
The interventions under investigation include: 0 mg placebo (DIETARY_SUPPLEMENT), 300 mg GSE (DIETARY_SUPPLEMENT), 600 mg GSE (DIETARY_SUPPLEMENT), 900 mg GSE (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02254317?
This trial is sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02254317's enrollment target sits among peer trials
16 1871st of 2000 higher than 120 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI